Investigating how Reelin and its receptors affect Alzheimer's disease
Reelin and Receptor Splicing in Alzheimer's Disease
This study is looking at how a protein called Reelin might help protect the brain from Alzheimer's disease by improving brain connections, and it aims to find new ways to boost Reelin levels to help people with Alzheimer's feel better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10856480 on NIH RePORTER |
What this research studies
This research focuses on the role of Reelin signaling in Alzheimer's disease, particularly how it enhances synaptic plasticity and may protect against the disease's progression. The study will explore the impact of alternative splicing of Reelin receptors on Alzheimer's risk and the functional consequences of these variations. By utilizing advanced techniques like CRISPR activation, the research aims to increase Reelin expression to potentially reverse tau pathology-related deficits. Patients may benefit from insights into new therapeutic strategies that target these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk for Alzheimer's disease or those in the early stages of the condition.
Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow or prevent the progression of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in understanding the neuroprotective roles of Reelin, suggesting that this approach could yield significant insights.
Where this research is happening
Boston, United States
- Boston University (Charles River Campus) — Boston, United States (Active)
Researchers
- Principal investigator: Ho, Angela — Boston University (Charles River Campus)
- Study coordinator: Ho, Angela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.